Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.

Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA.

Clin Cancer Res. 2018 Jun 15;24(12):2771-2779. doi: 10.1158/1078-0432.CCR-17-2398. Epub 2018 Mar 21.

2.

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang WG, Mahoney R, Gaydos C, Tardio L, Kim SK, Conant R, Curran K, Kaplan J, Verheijen J, Ayral-Kaloustian S, Mansour TS, Abraham RT, Zask A, Gibbons JJ.

Cancer Res. 2010 Jan 15;70(2):621-31. doi: 10.1158/0008-5472.CAN-09-2340. Epub 2010 Jan 12.

3.

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Gibbons JJ, Abraham RT, Yu K.

Semin Oncol. 2009 Dec;36 Suppl 3:S3-S17. doi: 10.1053/j.seminoncol.2009.10.011. Review.

PMID:
19963098
4.

Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.

Ayral-Kaloustian S, Gu J, Lucas J, Cinque M, Gaydos C, Zask A, Chaudhary I, Wang J, Di L, Young M, Ruppen M, Mansour TS, Gibbons JJ, Yu K.

J Med Chem. 2010 Jan 14;53(1):452-9. doi: 10.1021/jm901427g.

PMID:
19928864
5.

Targeting mTOR globally in cancer: thinking beyond rapamycin.

Shor B, Gibbons JJ, Abraham RT, Yu K.

Cell Cycle. 2009 Dec;8(23):3831-7. Epub 2009 Dec 14. Review.

PMID:
19901542
6.

Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.

Nowak P, Cole DC, Brooijmans N, Bursavich MG, Curran KJ, Ellingboe JW, Gibbons JJ, Hollander I, Hu Y, Kaplan J, Malwitz DJ, Toral-Barza L, Verheijen JC, Zask A, Zhang WG, Yu K.

J Med Chem. 2009 Nov 26;52(22):7081-9. doi: 10.1021/jm9012642.

PMID:
19848404
7.

ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.

Zask A, Verheijen JC, Curran K, Kaplan J, Richard DJ, Nowak P, Malwitz DJ, Brooijmans N, Bard J, Svenson K, Lucas J, Toral-Barza L, Zhang WG, Hollander I, Gibbons JJ, Abraham RT, Ayral-Kaloustian S, Mansour TS, Yu K.

J Med Chem. 2009 Aug 27;52(16):5013-6. doi: 10.1021/jm900851f.

PMID:
19645448
8.

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, Ayral-Kaloustian S, Mansour TS, Gibbons JJ, Abraham RT, Nowak P, Zask A.

Cancer Res. 2009 Aug 1;69(15):6232-40. doi: 10.1158/0008-5472.CAN-09-0299. Epub 2009 Jul 7.

9.

The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties.

Beyer CF, Zhang N, Hernandez R, Vitale D, Nguyen T, Ayral-Kaloustian S, Gibbons JJ.

Cancer Chemother Pharmacol. 2009 Sep;64(4):681-9. doi: 10.1007/s00280-008-0916-2. Epub 2009 Jan 10.

PMID:
19132373
10.

A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.

Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, Yu K.

Cancer Res. 2008 Apr 15;68(8):2934-43. doi: 10.1158/0008-5472.CAN-07-6487.

11.

TTI-237: a novel microtubule-active compound with in vivo antitumor activity.

Beyer CF, Zhang N, Hernandez R, Vitale D, Lucas J, Nguyen T, Discafani C, Ayral-Kaloustian S, Gibbons JJ.

Cancer Res. 2008 Apr 1;68(7):2292-300. doi: 10.1158/0008-5472.CAN-07-1420.

12.

Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines.

Toral-Barza L, Zhang WG, Huang X, McDonald LA, Salaski EJ, Barbieri LR, Ding WD, Krishnamurthy G, Hu YB, Lucas J, Bernan VS, Cai P, Levin JI, Mansour TS, Gibbons JJ, Abraham RT, Yu K.

Mol Cancer Ther. 2007 Nov;6(11):3028-38. Epub 2007 Nov 7.

13.

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.

Abraham RT, Gibbons JJ.

Clin Cancer Res. 2007 Jun 1;13(11):3109-14. Review.

14.

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, Gibbons JJ.

Endocr Relat Cancer. 2001 Sep;8(3):249-58.

PMID:
11566616
15.

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9. Epub 2001 Aug 14.

16.

Internalization of Staphylococcus aureus by endothelial cells induces cytokine gene expression.

Yao L, Bengualid V, Lowy FD, Gibbons JJ, Hatcher VB, Berman JW.

Infect Immun. 1995 May;63(5):1835-9.

17.

Biochemical and immunological properties of two forms of pertactin, the 69,000-molecular-weight outer membrane protein of Bordetella pertussis.

Gotto JW, Eckhardt T, Reilly PA, Scott JV, Cowell JL, Metcalf TN 3rd, Mountzouros K, Gibbons JJ Jr, Siegel M.

Infect Immun. 1993 May;61(5):2211-5.

18.
19.

Postdural puncture headache after fluoroscopically guided lumbar paravertebral sympathetic block.

Schmidt SD, Gibbons JJ.

Anesthesiology. 1993 Jan;78(1):198-200. No abstract available.

PMID:
8424555
20.

Testicular circulatory isolation: a phase I study.

Gibbons JJ, Parra RO, Andriole GL, Johnson FE.

Surg Oncol. 1992 Dec;1(6):413-6.

PMID:
1341279
21.

An unusual presentation of spinal cord tumor after epidural anesthesia.

Martin HB, Gibbons JJ, Bucholz RD.

Anesth Analg. 1992 Nov;75(5):844-6. No abstract available.

PMID:
1416143
22.

Pluronic F 127 liquid sensitizes mice to low doses of Escherichia coli lipopolysaccharide.

Pickett WC, Torley LW, Dejoy SQ, Gibbons JJ Jr, Desai NR, Oronsky AL, Kerwar SS.

Crit Care Med. 1992 Oct;20(10):1448-53.

PMID:
1395667
23.

Interscalene blocks for chronic upper extremity pain.

Gibbons JJ, Wilson PR, Lamer TJ, Elliott BA.

Clin J Pain. 1992 Sep;8(3):264-9.

PMID:
1421742
24.

RSD score: criteria for the diagnosis of reflex sympathetic dystrophy and causalgia.

Gibbons JJ, Wilson PR.

Clin J Pain. 1992 Sep;8(3):260-3.

PMID:
1421741
25.

Somatosensory evoked potentials and stellate ganglion block.

Gibbons JJ.

Clin J Pain. 1992 Jun;8(2):181-2. No abstract available.

PMID:
1633382
26.
28.

Sudden asystole after spinal anesthesia treated with the "pacing thump".

Gibbons JJ, Ditto FF 3rd.

Anesthesiology. 1991 Oct;75(4):705. No abstract available.

PMID:
1928783
29.

A hidden leak in the circle system.

Yassin K, Gibbons JJ.

Anesth Analg. 1991 Aug;73(2):236. No abstract available.

PMID:
1854044
30.

Antiinflammatory and antiarthritic properties of a substituted quinoline carboxylic acid: CL 306,293.

Sloboda AE, Powell D, Poletto JF, Pickett WC, Gibbons JJ Jr, Bell DH, Oronsky AL, Kerwar SS.

J Rheumatol. 1991 Jun;18(6):855-60.

PMID:
1895266
31.

Post-dural puncture headache in the HIV-positive patient.

Gibbons JJ.

Anesthesiology. 1991 May;74(5):953. No abstract available.

PMID:
2021218
32.

Factitious prolongation of bleeding time associated with patient movement.

Ditto FF 3rd, Gibbons JJ.

Anesth Analg. 1991 May;72(5):710-2. No abstract available.

PMID:
2018231
33.

The importance of documenting complete sympathetic blockade.

Smith BD, Gibbons JJ.

Anesth Analg. 1991 Mar;72(3):406-7. No abstract available.

PMID:
1994773
34.

Alterations in the expression of colony-stimulating factor-1 and its receptor during an acute graft-vs-host reaction in mice.

Praloran V, Raventos-Suarez C, Bartocci A, Lucas J, Stanley ER, Gibbons JJ Jr.

J Immunol. 1990 Nov 15;145(10):3256-61.

PMID:
2146318
35.

Tourniquet pain during bupivacaine and tetracaine spinal anesthesia.

Gibbons JJ.

Anesth Analg. 1989 Sep;69(3):410-1. No abstract available.

PMID:
2774245
37.

The effect of 3,6-bis(2-piperidinoethoxy) acridine trihydrochloride (CL 246, 738) on acute graft vs host reactions in mice.

Lucas J, Raventos-Suarez C, Wang BS, Ruszala-Mallon VM, Gibbons JJ Jr.

Int J Immunopharmacol. 1989;11(7):733-41.

PMID:
2599713
38.

Studies on suppressor factors produced by T-cell hybridomas. I. Characterization of antigen-specific suppressor factors.

Kim YT, Sheu KF, Gibbons JJ, DeBlasio T, Woo CW, Weksler ME, Siskind GW.

Cell Immunol. 1988 Apr 15;113(1):52-62.

PMID:
2452703
39.

Axillary block of the brachial plexus: "you can't get there from here...".

Gibbons JJ, Lennon RL, Rose SH, Wedel DJ, Gibson BE.

Anesthesiology. 1988 Feb;68(2):314-5. No abstract available.

PMID:
3341600
40.
41.

Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function.

Fidler JM, DeJoy SQ, Gibbons JJ Jr.

J Immunol. 1986 Jul 15;137(2):727-32.

PMID:
3487580
42.
45.

Production of auto-anti-idiotypic antibody during the normal immune response. VIII. Effect of auto-anti-idiotypic antibody on contact sensitivity.

Shepherd GM, Gibbons JJ, Siskind GW, Thorbecke GJ, Goidl EA.

Cell Immunol. 1985 Sep;94(2):512-20.

PMID:
3896524
46.

Production of auto-anti-idiotypic antibody during the normal immune response. XII. An enzyme-linked immunosorbent assay for auto-anti-idiotype antibody.

Gibbons JJ, Goidl EA, Shepherd GM, Thorbecke GJ, Siskind GW.

J Immunol Methods. 1985 May 23;79(2):231-7.

PMID:
3873501
47.
49.

Supplemental Content

Loading ...
Support Center